Concepedia

Haiying Liu

HL

10

Publications

731

Citations

10

H-Index

2003

Active since

Affiliations

Seoul National University Hospital(Current)

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

Guangzhou Medical University Cancer Hospital

Roche (Switzerland)

Guangzhou Medical University

Haiying Liu is an author at Seoul National University Hospital specializing in medicine, breast cancer, and immunology.

ORCID

Top concepts

Publications per year

2003–2024

10

Publications

10

Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial

Leisha A. Emens, Francisco J. Esteva, Mark Beresford et al. · The Lancet Oncology · 2020 · 363 citations

, , +7

Inhibitory effect of modified citrus pectin on liver metastases in a mouse colon cancer model

Haiying Liu, Zhiliang Huang, Guohua Yang et al. · World Journal of Gastroenterology · 2008 · 105 citations · Full text

C-Reactive Protein and Ischemia in Users and Nonusers of β-Blockers and Statins

Mary Beattie, Michael G. Shlipak, Haiying Liu et al. · Circulation · 2003 · 69 citations

Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: The Phase III KAITLIN Study

Ian E. Krop, Seock‐Ah Im, Carlos H. Barrios et al. · Journal of Clinical Oncology · 2021 · 62 citations · Full text

Primary analysis of KAITLIN: A phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC).

Nadia Harbeck, Seock‐Ah Im, Carlos H. Barrios et al. · Journal of Clinical Oncology · 2020 · 28 citations

, , +18

Rows per page

1–5 of 10